Nevirapine
| Nevirapine | |
|---|---|
| Salts [] | |
|---|---|
| Nevirapine hemihydrate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 266.30 g/mol [1] |
| Appearance | Crystals from pyridine and water [1] |
| Melting point | 196.06 [1] |
| Solubility | 0.7046 mg/L [1] |
| Predicted LogP | 2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C15H14N4O |
| IUPAC name | 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one |
| SMILES | CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4 |
| InChI | InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20) |
| InChIKey | NQDJXKOVJZTUJA-UHFFFAOYSA-N |
| CAS number | 129618-40-2 |
| UNII | 99DK7FVK1H |
| PubChem CID | 4463 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 45 hours |
| Metabolism | Liver |
| Excretion | Kidney: <6% (Parent drug) , Bile duct <5% (Parent drug) |
| Routes of administration | By mouth |
Nevirapine (also known as Viramune, Bi-rg-587, Nevirapine anhydrous, Viramune XR, Birg 0587, Nevirapine teva, Nevirapina, Nevirapine, anhydrous, Birg587 or Birg-0587).
Chemistry
Salts []
Nevirapine is typically found in the form of its hemihydrate salt.
Stereochemistry []
Nevirapine is achiral.
Druglikeness
Lipinski's rule of five
Nevirapine matches Lipinski's rule of five.Pharmacology
ATC Classification
- antiinfectives for systemic use (J)
- antivirals for systemic use (J05)
- direct acting antivirals (J05A)
- non-nucleoside reverse transcriptase inhibitors (J05AG)
- (J05AG01)
- nevirapine (J05AG01)
MeSH Classification
- reverse transcriptase inhibitors (M0028255)
- anti-hiv agents (M0028839)
- cytochrome p-450 cyp3a inducers (M0590399)
Mechanism of action []
Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. [1]
Interactions []
Medical side effects []
110 side effects listed on drug labels in SIDER 4.1 (nevirapine).
- Dermatitis
- Rash
- Liver function test abnormal
- Alanine aminotransferase increased
- Headache
- Abdominal pain
- Gastrointestinal pain
- Diarrhoea
- Nausea
- Hepatotoxicity
- Myalgia
- Musculoskeletal discomfort
- Arthralgia
- Drug eruption
- Blood pressure increased
- Blood phosphorus decreased
- Agranulocytosis
- Asthenia
- Fatigue
- Toxic epidermal necrolysis
- Erythema multiforme
- Stevens-Johnson syndrome
- Anaphylactic shock
- Anaemia
- Angioedema
- Blister
- Dermatitis bullous
- Bullous eruption
- Conjunctivitis
- Oedema
- Eosinophilia
- Body temperature increased
- Hepatitis
- Hypersensitivity
- Jaundice
- Neutropenia
- Paraesthesia
- Paraesthesia skin
- Rhabdomyolysis
- Mouth ulceration
- Urticaria
- Vomiting
- Hepatic failure
- Oral disorder
- Hepatitis cholestatic
- Hepatic necrosis
- Malaise
- Discomfort
- Feeling abnormal
- Ill-defined disorder
- Pain
- Hepatitis fulminant
- Lymphadenopathy
- Face oedema
- Drug reaction with eosinophilia and systemic symptoms
- Drug interaction
- Somnolence
- Congenital anomaly
- Developmental delay
- Decreased appetite
- Autoimmune disorder
- Bone disorder
- Connective tissue disorder
- Dermatitis exfoliative
- Erythema nodosum
- Gastrointestinal disorder
- Basedow's disease
- Hepatitis toxic
- Hypercholesterolaemia
- Hyperglycaemia
- Hypertriglyceridaemia
- Blood triglycerides increased
- Breast enlargement
- Immune system disorder
- Inflammation
- Insulin resistance
- Lipodystrophy acquired
- Liver disorder
- Hepatocellular injury
- Foetor hepaticus
- Necrosis
- Nervous system disorder
- Opportunistic infection
- Pancreatitis
- Neuropathy peripheral
- Pruritus
- Renal failure
- Thrombocytopenia
- Ulcer
- Erythema
- Gamma-glutamyltransferase increased
- Aspartate aminotransferase increased
- Liver injury
- Traumatic liver injury
- Skin disorder
- Rash erythematous
- Hepatic enzyme increased
- Skin exfoliation
- Vertical infection transmission
- Hepatobiliary disease
- Hepatitis acute
- Rash maculo-papular
- Transaminases increased
- Lipohypertrophy
- Chronic hepatitis B
- Surgery
- Hyperlactacidaemia
- Fat redistribution
- Rash papular
- Hypertransaminasaemia
Indications
- Acquired immunodeficiency syndrome
- Hepatotoxicity
- Infection
- Rash
Legal status []
- Australia: Nevirapine is a Schedule 4.[3]
- United States: Nevirapine is Prescription only.
- European Union: Nevirapine is Prescription only.
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4463, Nevirapine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4463
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Nevirapine. UNII: 99DK7FVK1H. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/99DK7FVK1H
Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 21 June 2022. https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 18:01:18 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 18:01:14 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 18:01:14 |
| gsrs | ok | 2026-11-20 18:01:15 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014383) | 2026-11-20 18:01:14 |
| kegg | ok | 2026-11-20 18:01:17 |
| pubchem | ok | 2026-11-20 18:01:14 |
| missing (no r/tripreports posts mention it) | 2026-11-20 18:01:14 | |
| sider | ok | 2026-11-20 18:01:14 |
| structure | ok | 2026-11-20 18:01:14 |
| wikipedia | ok | 2026-11-20 18:01:15 |